MANN FUNG, MD, MBA, MHCM, FACP
Chief Executive Officer
Dr. Mann Fung is the Chief Executive Officer of Tavotek Biotherapeutics. He has nearly 30 years of experience in the Regulatory, Pharmaceutical and Finance Industries including FDA, Big Pharma, and Venture Capital. Prior to joining Tavotek in 2019, Dr. Fung was a Venture Partner at Fidelity Eight Roads Ventures as well as a clinical consultant for BioMotiv Capital. He is currently an Investment Committee member of the Apricot-Sanhe Entrepreneur Fund and a Scientific Advisory Board member of Virogin Biotech and YiSheng Biopharma.
MARK CHIU, PhD
Chief Scientific Officer
Dr. Mark Chiu is the President of R&D as well as Chief Scientific Officer at Tavotek Biotherapeutics. He has nearly 35 years of experience in new drug discovery for AbbVie/Abbott Laboratories and Janssen. Prior to joining Tavotek, Dr. Chiu was the Head of the Process Analytical Sciences at Biotherapeutics Development and Head of Antibody Engineering in the Biologics Research Department at Janssen, the pharmaceutical branch of Johnson & Johnson (J&J).
DI ZHANG, PhD
Dr. Di Zhang is the Vice President of Discovery at Tavotek Biotherapeutics. He has nearly 20 years of experience in new drug discovery for several renowned pharmaceutical companies, including AbbVie/Abbott Laboratories and Janssen. Prior to joining Tavotek, Dr. Zhang was a Senior Investigator in the Biologics Research Department at Janssen, the pharmaceutical branch of Johnson & Johnson (J&J).
SUSAN TAM, MS
Ms. Susan Tam is Vice President of Discovery Research at Tavotek Biotherapeutics. She has extensive pharmaceutical industrial experience (over 30 years) mainly focused on in vitro diagnostics, and antibody- protein therapeutics. Her diverse research and therapeutic background include oncology, immunology, neuroscience, infectious diseases, cardiovascular and metabolic disease.
Chao Han, PhD
Vice President of Early Development
Dr. Chao Han is the Vice President of Early Development and the Site Head of Tavotek Lab at Lower Gwynedd, Pennsylvania. He has more than 20 years of experience in preclinical discovery and clinical development of small molecule and biologic therapeutics. Prior to joining Tavotek, Dr. Han was the Scientific Director of Biologics Development Sciences at Janssen. He has worked at GSK as the DMPK Head and the Section Head of Pharmacokinetics and In Vivo Technology.
MARK TORNETTA, MS
Mr. Mark Tornetta is Vice President of Biologics Discovery at Tavotek Biotherapeutics. He has over 29 years of discovery biopharmaceutical experience, 23 years in antibody engineering and 6 years in target discovery working on orphan GPCRs. His biopharma activities involved targets in cardiovascular, pulmonary, metabolic, immune, oncological, and infectious diseases.
MARIA MACWILLIAMS, PhD
VP Molecular Biology
Maria P. MacWilliams Ph.D. is Vice President of Molecular Biology at Tavotek Biotherapeutics. Dr. MacWilliams has over 30 years experience with synthetic protein design and development of novel cell based assays. Her scientific career spans many diverse areas of science including protein engineering, structure-function studies of DNA recombinases and nucleases, analyses of small molecule drug complexes, soil metagenomics, and environmental microbiology. Dr. MacWilliams has strong expertise in developing assays to elucidate complex molecular interactions.
Chief Operation Officer
Mr. Wei Zhang is the Chief Operations Officer at Tavotek Biotherapeutics. Before joining Tavotek, he was the Head of Digital Health and Information Technology at the Johnson and Johnson (J&J) Asia Pacific Innovation Center. While at J&J, he worked extensively with the global therapeutic team to identify and explore novel ideas and concepts from external partners to facilitate new business opportunities. The scope of his work included Big Data, Artificial Intelligence for drug development, business intelligence, and robotics.